Company intelligence / Profile preview
Oncodesign
Dijon, Franceoncodesign.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Oncodesign has split into two independent companies: Oncodesign Precision Medicine (OPM) focusing on drug discovery for resistant and metastatic cancers, and Oncodesign Services (ODS) operating as a CRO for drug discovery and preclinical services
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Small moleculesBiologicsRadiotherapeuticsProtein degraders (PROTAC)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Pharmaceutical firmsbiotech companiespublic research institutions
Beyond the preview
Go deeper on Oncodesign.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncodesign.